Table 6.
Overall Summary of Treatment‐Emergent Adverse Events from ACHIEVE Trials for Triptan as Rescue Medication Within 30 Days
| n (%) | Ubrogepant Alone | Ubrogepant and Triptan† Rescue Medication | ||||
|---|---|---|---|---|---|---|
| Ubrogepant 25 mg (n = 319) | Ubrogepant 50 mg‡ (n = 670) | Ubrogepant 100 mg (n = 355) | Ubrogepant 25 mg (n = 54) | Ubrogepant 50 mg‡ (n = 109) | Ubrogepant 100 mg (n = 39) | |
| Any TEAE | 66 (20.7) | 182 (27.2) | 106 (29.9) | 14 (25.9) | 32 (29.4) | 10 (25.6) |
| Any treatment‐related TEAE | 24 (7.5) | 64 (9.6) | 53 (14.9) | 1 (1.9) | 8 (7.3) | 5 (12.8) |
| Serious AE | 1 (0.3) | 3 (0.4) | 1 (0.3) | 0 | 0 | 1 (2.6) |
AE = adverse event; TEAE = treatment‐emergent adverse event.
†
Triptans included almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.
‡
Pooled data across ACHIEVE I and ACHIEVE II trials.